POINT Biopharma Global Inc.
Healthcare · Pharmaceutical Preparations · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | |
|---|---|---|---|
| Revenue | $226.6M | $0 | — |
| Operating income | $125.5M | −$45.5M | −$13.1M |
| Net income | $98.3M | −$45.9M | −$13.4M |
| Total assets | $578.3M | $263.3M | $22.2M |
| Total liabilities | $91.4M | $8.0M | $8.7M |
| Equity | $487.0M | $255.2M | $5.0M |
| EPS (diluted) | $1.02 | $-0.62 | $-0.34 |
| Shares out. | 90.1M | 90.1M | 54.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- 55.4%
- Net margin
- 43.4%
- Return on equity
- 20.2%
- Return on assets
- 17.0%
- Return on capital (ROCE)
- 25.2%
- Liabilities / assets
- 15.8%
- Debt / equity
- 0.19×
- Book value / share
- $5.40
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Altman Z″ (distress)
- 12.39safe
- Accruals / assets
- −14.7%clean
- Piotroski F-Score
- 5/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 6 good- Operating margin is positive
- Strong return on equity (>15%)
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Goodman Jonathan R.Director | Dec 26, 2023 | U | 41,872 | — |
| Mccann Joe A.Officer — Chief Executive Officer | Dec 22, 2023 | U | 2,160 | — |
| Fleshner Neil E.Officer — Chief Medical Officer | Dec 22, 2023 | U | 2.8M | — |
| Hogue Gerald L.Director | Dec 26, 2023 | U | 21,596 | — |
| Malik RajeshDirector | Dec 26, 2023 | U | 3,700 | — |
| Lubner David CharlesDirector | Dec 26, 2023 | U | 35,400 | — |
| Silber Allan COfficer — Executive Chairman | Dec 22, 2023 | U | 4.3M | — |
| Margolin YaelDirector | Dec 27, 2023 | D | 1,710 | — |
| Bvf Partners L P/Il | Dec 18, 2023 | Sell | 9.0M | $12.45 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsDec 27, 2023
- Entered a material agreement · Other material eventOct 3, 2023
- Results of operationsAug 14, 2023
- Changed auditorAug 3, 2023
- Director / officer changeJun 13, 2023
- Shareholder voteJun 5, 2023
- Entered a material agreementFeb 7, 2023
- Entered a material agreement · Other material eventSep 14, 2022
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12GJan 8, 2024
- EFFECTDec 29, 2023
- EFFECTDec 29, 2023
- 4OWNERSHIP DOCUMENTDec 27, 2023
- 4OWNERSHIP DOCUMENTDec 27, 2023
- 4OWNERSHIP DOCUMENTDec 27, 2023
- 4OWNERSHIP DOCUMENTDec 27, 2023
- 4OWNERSHIP DOCUMENTDec 27, 2023
- 4OWNERSHIP DOCUMENTDec 27, 2023
- 4OWNERSHIP DOCUMENTDec 27, 2023
- 4OWNERSHIP DOCUMENTDec 27, 2023
- 4OWNERSHIP DOCUMENTDec 27, 2023
- 4OWNERSHIP DOCUMENTDec 27, 2023
- 4OWNERSHIP DOCUMENTDec 27, 2023
- SC 13D/ADec 27, 2023
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.